CNTB

Connect Biopharma Holdings Limited

Price Chart

Latest Quote

$2.00

-0.08 (-3.85%)

Current Price

Previous Close	$2.08
Open	$2.08
Day High	$2.16
Day Low	$1.93
Volume	203,520

Fetched: 2026-06-19T06:03:21

Stock Information

Shares Outstanding	62.96M
Total Debt	$693K
Cash Equivalents	$46.03M
Revenue	$233K
Net Income	$-64.61M
Sector	Healthcare
Industry	Biotechnology
Market Cap	$125.93M
EPS (TTM)	$-1.15
Exchange	NGM

🌐 Visit Website

📊 Comprehensive Analysis

Company Data

Enterprise Value	$79.96M
Sales	$233K
Income	$-64.61M
Book/sh	$0.68
Cash/sh	$0.73
Employees	64

Financial Ratios

Quick Ratio	2.86
Current Ratio	3.23
Debt/Eq	1.63

Returns & Margins

ROA	-54.20%
ROE	-102.94%
Gross Margin	100.00%
Operating Margin	-11601.78%

Ownership

Insider Ownership	31.82%
Institutional Ownership	54.26%
Insider & Institutional transactions data not available

Valuation Ratios

Forward P/E	-2.01
P/S	540.46
P/B	2.94

Analyst Data

Recommendation	strong_buy
Target Price	$7.07

Technical Indicators

SMA20	$2.22
SMA50	$2.42
SMA200	$2.32
RSI	27.93
ATR	0.1953

Shares Float	18.86M
Short Float	2.63%
Short Ratio	7.10
Rel Volume	0.79

Performance History

Week	-4.76%
Month	-8.68%
Quarter	-30.31%
6 Months	-15.25%
YTD	-20.63%
Year	+85.19%
3 Years	+90.48%
5 Years	-88.89%
10 Years	-89.18%

Stock Score: ⭐ Premium

Based on debt, profitability, growth, and cash flow metrics

⭐ Premium Feature

Recent Price History

Date	Close	Volume
2026-06-18	$2.00	204,200
2026-06-17	$2.08	354,500
2026-06-16	$1.99	256,100
2026-06-15	$2.06	330,000
2026-06-12	$2.12	173,600
2026-06-11	$2.10	345,000
2026-06-10	$2.08	183,800
2026-06-09	$2.12	339,400
2026-06-08	$2.20	203,500
2026-06-05	$2.17	277,500
2026-06-04	$2.30	357,000
2026-06-03	$2.23	442,500
2026-06-02	$2.15	227,200
2026-06-01	$2.34	125,900
2026-05-29	$2.49	267,200
2026-05-28	$2.38	115,700
2026-05-27	$2.40	252,700
2026-05-26	$2.40	507,700
2026-05-22	$2.35	94,500
2026-05-21	$2.36	116,300
2026-05-20	$2.31	201,300
2026-05-19	$2.19	130,400

About Connect Biopharma Holdings Limited

Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD). The company was founded in 2012 and is headquartered in San Diego, California.

📰 Latest News

Connect Biopharma Touts Rademikibart’s Edge as SEABREEZE Data Looms in 2026

MarketBeat • 2026-05-22T04:05:13Z

Companies Like Connect Biopharma Holdings (NASDAQ:CNTB) Could Be Quite Risky

Simply Wall St. • 2026-05-15T13:40:08Z

Connect Biopharma touts rapid IV rademikibart FEV1 gains; Phase 3 atopic dermatitis data impresses

MarketBeat • 2026-03-30T14:11:16Z

Connect Biopharma Touts “Next-Gen Dupixent” Rademikibart, Near-Term Asthma/COPD Readouts

MarketBeat • 2026-03-14T14:15:41Z

Connect Biopharma Touts Rademikibart as Fast-Acting Option for Acute Asthma, COPD Flare-Ups at Conference

MarketBeat • 2026-02-27T11:46:46Z

3 Promising Penny Stocks With Market Caps Up To $400M

Simply Wall St. • 2026-01-21T18:05:44Z

Discovering Connect Biopharma Holdings And 2 Other Promising Penny Stocks

Simply Wall St. • 2025-12-23T12:04:50Z

Connect Biopharma Holdings Limited's (NASDAQ:CNTB) largest shareholders are private equity firms with 39% ownership, individual investors own 22%

Simply Wall St. • 2025-12-16T10:00:41Z

Relmada Therapeutics Leads These 3 Promising Penny Stocks

Simply Wall St. • 2025-11-05T12:05:25Z

October 2025's Promising Penny Stocks To Consider

Simply Wall St. • 2025-10-06T18:05:00Z

Period:

Income Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Revenue
Total Revenue	$64,000	$26,033,000	$0	$0
Operating Revenue	$64,000	$26,033,000	$0	$0
Expenses
Total Expenses	$58,138,000	$48,485,000	$69,056,000	$116,507,000
Other Income Expense	$523,000	$2,594,000	$1,847,000	$-2,809,000
Other Non Operating Income Expenses	$523,000	$2,594,000	$1,847,000	$150,000
Net Non Operating Interest Income Expense	$2,268,000	$4,453,000	$5,223,000	$1,523,000
Operating Expense	$58,138,000	$48,485,000	$69,056,000	$116,507,000
General And Administrative Expense	$20,340,000	$19,229,000	$16,054,000	$20,806,000
Interest Expense	-	-	$23,000	$21,000
Interest Expense Non Operating	-	-	$23,000	$21,000
Other Operating Expenses	-	-	$-1,580,000	$-929,000
Income & Earnings
Net Income From Continuing Operation Net Minority Interest	$-55,480,000	$-15,628,000	$-62,106,000	$-118,091,000
Net Interest Income	$2,268,000	$4,453,000	$5,223,000	$1,523,000
Interest Income	$2,268,000	$4,453,000	$5,223,000	$1,544,000
Normalized Income	$-55,480,000	$-15,628,000	$-62,106,000	$-115,753,390
Net Income From Continuing And Discontinued Operation	$-55,480,000	$-15,628,000	$-62,106,000	$-118,091,000
Total Operating Income As Reported	$-58,074,000	$-22,452,000	$-69,056,000	$-119,316,000
Net Income Common Stockholders	$-55,480,000	$-15,628,000	$-62,106,000	$-118,091,000
Net Income	$-55,480,000	$-15,628,000	$-62,106,000	$-118,091,000
Net Income Including Noncontrolling Interests	$-55,480,000	$-15,628,000	$-62,106,000	$-118,091,000
Net Income Continuous Operations	$-55,480,000	$-15,628,000	$-62,106,000	$-118,091,000
Pretax Income	$-55,283,000	$-15,405,000	$-61,986,000	$-117,793,000
Interest Income Non Operating	$2,268,000	$4,453,000	$5,223,000	$1,544,000
Operating Income	$-58,074,000	$-22,452,000	$-69,056,000	$-116,507,000
Special Income Charges	-	-	$0	$-4,698,000
Per Share
Diluted EPS	$-1.00	$-0.28	$-1.13	$-2.10
Basic EPS	$-1.00	$-0.28	$-1.13	$-2.10
Other
Tax Effect Of Unusual Items	$0	$0	$0	$-621,390
Tax Rate For Calcs	$0	$0	$0	$0
Normalized EBITDA (Bullshit earnings)	$-57,370,000	$-21,792,000	$-68,336,000	$-113,782,000
Reconciled Depreciation	$704,000	$660,000	$720,000	$1,031,000
EBITDA (Bullshit earnings)	$-57,370,000	$-21,792,000	$-68,336,000	$-116,741,000
EBIT	$-58,074,000	$-22,452,000	$-69,056,000	$-117,772,000
Diluted Average Shares	$55,660,000	$55,213,000	$55,067,000	$54,969,310
Basic Average Shares	$55,660,000	$55,213,000	$55,067,000	$54,969,310
Diluted NI Availto Com Stockholders	$-55,480,000	$-15,628,000	$-62,106,000	$-118,091,000
Tax Provision	$197,000	$223,000	$120,000	$298,000
Research And Development	$37,798,000	$29,256,000	$53,002,000	$96,630,000
Selling General And Administration	$20,340,000	$19,229,000	$16,054,000	$20,806,000
Other Gand A	$20,340,000	$19,229,000	$16,054,000	$20,806,000
Total Unusual Items	-	-	$2,875,000	$-2,959,000
Total Unusual Items Excluding Goodwill	-	-	$2,875,000	$-2,959,000
Impairment Of Capital Assets	-	-	$0	$4,698,000
Gain On Sale Of Security	-	-	$2,875,000	$1,739,000

Fetched: 2026-06-19

Balance Sheet (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Assets
Net Tangible Assets	$41,935,000	$92,113,000	$101,435,000	$154,327,000
Total Assets	$56,075,000	$101,284,000	$127,375,000	$174,013,000
Total Non Current Assets	$5,146,000	$4,323,000	$4,822,000	$18,234,000
Other Non Current Assets	$646,000	$33,000	$24,000	$34,000
Goodwill And Other Intangible Assets	$45,000	$53,000	$62,000	$3,165,000
Current Assets	$50,929,000	$96,961,000	$122,553,000	$155,779,000
Other Current Assets	$29,000	$419,000	$54,000	-
Prepaid Assets	$6,397,000	$1,783,000	$3,845,000	$3,130,000
Receivables	$161,000	$1,051,000	$351,000	$232,000
Accrued Interest Receivable	$148,000	$262,000	$351,000	-
Accounts Receivable	$13,000	$789,000	$0	-
Cash Cash Equivalents And Short Term Investments	$44,342,000	$93,708,000	$118,303,000	$152,417,000
Cash And Cash Equivalents	$38,345,000	$78,232,000	$105,663,000	$79,010,000
Non Current Prepaid Assets	-	-	$0	$59,000
Non Current Accounts Receivable	-	-	$108,000	$159,000
Investmentin Financial Assets	-	-	$0	$9,440,000
Other Intangible Assets	-	-	$62,000	$3,165,000
Other Receivables	-	-	$178,000	$232,000
Cash Equivalents	-	-	$78,317,000	$18,368,000
Cash Financial	-	-	$27,690,000	$60,642,000
Debt
Total Debt	$690,000	$178,000	$465,000	$431,000
Long Term Debt And Capital Lease Obligation	$368,000	$24,000	$180,000	$245,000
Current Debt And Capital Lease Obligation	$322,000	$154,000	$285,000	$186,000
Liabilities
Total Liabilities Net Minority Interest	$14,095,000	$9,118,000	$25,878,000	$16,521,000
Total Non Current Liabilities Net Minority Interest	$482,000	$656,000	$585,000	$897,000
Other Non Current Liabilities	$114,000	$632,000	$405,000	-
Current Liabilities	$13,613,000	$8,462,000	$25,293,000	$15,624,000
Current Deferred Liabilities	$167,000	$164,000	$13,320,000	$0
Payables And Accrued Expenses	$10,210,000	$4,802,000	$9,637,000	$15,438,000
Payables	$1,964,000	$342,000	$2,209,000	$14,622,000
Accounts Payable	$1,964,000	$342,000	$2,209,000	$11,937,000
Non Current Deferred Liabilities	-	-	$405,000	$652,000
Other Payable	-	-	$2,354,000	$2,685,000
Equity
Common Stock Equity	$41,980,000	$92,166,000	$101,497,000	$157,492,000
Total Equity Gross Minority Interest	$41,980,000	$92,166,000	$101,497,000	$157,492,000
Stockholders Equity	$41,980,000	$92,166,000	$101,497,000	$157,492,000
Gains Losses Not Affecting Retained Earnings	$-1,191,000	$-1,666,000	$-1,008,000	$-7,628,000
Other Equity Adjustments	$-1,191,000	$-1,666,000	$-1,008,000	$-7,628,000
Retained Earnings	$-400,835,000	$-345,355,000	$-329,727,000	$-479,844,000
Other Equity Interest	-	-	$19,731,000	$16,473,000
Other
Treasury Shares Number	$2,148,386	$2,513,495	$2,405,591	$2,407,091
Ordinary Shares Number	$56,442,308	$55,349,208	$55,102,954	$55,041,247
Share Issued	$58,590,694	$57,862,703	$57,508,545	$57,448,338
Tangible Book Value	$41,935,000	$92,113,000	$101,435,000	$154,327,000
Invested Capital	$41,980,000	$92,166,000	$101,497,000	$157,492,000
Working Capital	$37,316,000	$88,499,000	$97,260,000	$140,155,000
Capital Lease Obligations	$690,000	$178,000	$465,000	$431,000
Total Capitalization	$41,980,000	$92,166,000	$101,497,000	$157,492,000
Treasury Stock	$180,000	$180,000	$180,000	$180,000
Additional Paid In Capital	$444,176,000	$439,357,000	$432,402,000	$628,661,000
Capital Stock	$10,000	$10,000	$10,000	$10,000
Common Stock	$10,000	$10,000	$10,000	$10,000
Preferred Stock	$0	$0	$0	-
Long Term Capital Lease Obligation	$368,000	$24,000	$180,000	$245,000
Current Deferred Revenue	$167,000	$164,000	$13,320,000	$0
Current Capital Lease Obligation	$322,000	$154,000	$285,000	$186,000
Pensionand Other Post Retirement Benefit Plans Current	$2,914,000	$3,342,000	$2,051,000	-
Current Accrued Expenses	$8,246,000	$4,460,000	$7,428,000	$816,000
Net PPE	$4,455,000	$4,237,000	$4,736,000	$5,377,000
Accumulated Depreciation	$-3,291,000	$-2,628,000	$-2,031,000	$-1,621,000
Gross PPE	$7,746,000	$6,865,000	$6,767,000	$6,998,000
Leases	$859,000	$830,000	$626,000	$762,000
Other Properties	$647,000	$189,000	$462,000	$5,494,000
Machinery Furniture Equipment	$6,240,000	$5,846,000	$5,679,000	$341,000
Properties	$0	$0	$0	$0
Other Short Term Investments	$5,997,000	$15,476,000	$12,640,000	$73,407,000
Non Current Deferred Revenue	-	-	$405,000	$652,000
Investments And Advances	-	-	$0	$9,440,000
Construction In Progress	-	-	$0	$0
Buildings And Improvements	-	-	$1,193,000	$401,000
Available For Sale Securities	-	-	-	$9,440,000

Fetched: 2026-06-19

Cash Flow Statement (Annual)

Metric	2025-12-31	2024-12-31	2023-12-31	2022-12-31
Free Cash Flow
Free Cash Flow	$-51,640,000	$-24,362,000	$-47,822,000	$-105,925,000
Operating Activities
Operating Cash Flow	$-51,206,000	$-23,612,000	$-47,741,000	$-101,520,000
Cash Flow From Continuing Operating Activities	$-51,206,000	$-23,612,000	$-47,741,000	$-101,520,000
Operating Gains Losses	$37,000	$9,000	$101,000	$-1,491,000
Investing Activities
Capital Expenditure	$-434,000	$-750,000	$-81,000	$-4,405,000
Investing Cash Flow	$9,818,000	$-3,451,000	$74,980,000	$-86,243,000
Cash Flow From Continuing Investing Activities	$9,818,000	$-3,451,000	$74,980,000	$-86,243,000
Net Other Investing Changes	-	-	$-84,000	-
Financing Activities
Financing Cash Flow	$1,093,000	$227,000	$45,000	$-85,000
Cash Flow From Continuing Financing Activities	$1,093,000	$227,000	$45,000	$-85,000
Repurchase Of Capital Stock	-	-	$0	$0
Issuance Of Capital Stock	-	-	$44,000	$18,000
Net Common Stock Issuance	-	-	$44,000	$18,000
Common Stock Issuance	-	-	$44,000	$18,000
Net Other Financing Charges	-	-	-	-
Other
Income Tax Paid Supplemental Data	$292,000	$111,000	$120,000	$462,000
End Cash Position	$38,345,000	$78,232,000	$105,663,000	$79,010,000
Beginning Cash Position	$78,232,000	$105,663,000	$78,947,000	$267,716,000
Effect Of Exchange Rate Changes	$408,000	$-595,000	$-568,000	$-858,000
Changes In Cash	$-40,295,000	$-26,836,000	$27,284,000	$-187,848,000
Proceeds From Stock Option Exercised	$1,093,000	$227,000	$45,000	$119,000
Net Investment Purchase And Sale	$10,250,000	$-2,701,000	$72,118,000	$-81,838,000
Sale Of Investment	$40,720,000	$12,750,000	$103,145,000	$34,226,000
Purchase Of Investment	$-30,470,000	$-15,451,000	$-31,027,000	$-116,064,000
Net PPE Purchase And Sale	$-432,000	$-750,000	$2,862,000	$-4,405,000
Sale Of PPE	$2,000	$0	$2,943,000	$0
Purchase Of PPE	$-434,000	$-750,000	$-81,000	$-4,405,000
Change In Working Capital	$580,000	$-15,490,000	$9,851,000	$6,459,000
Change In Other Working Capital	$-548,000	$-13,170,000	$13,553,000	-
Change In Other Current Liabilities	$-518,000	$227,000	$-182,000	-
Change In Payables And Accrued Expense	$4,980,000	$-3,544,000	$-7,214,000	$-289,000
Change In Accrued Expense	$3,358,000	$-1,677,000	$-6,078,000	-
Change In Payable	$1,622,000	$-1,867,000	$-1,136,000	$-289,000
Change In Account Payable	$1,622,000	$-1,867,000	$-1,136,000	$-776,000
Change In Prepaid Assets	$-4,110,000	$1,786,000	$3,694,000	-
Change In Receivables	$776,000	$-789,000	$0	$4,050,000
Changes In Account Receivables	$776,000	$-789,000	$0	-
Stock Based Compensation	$3,726,000	$6,728,000	$5,396,000	$6,907,000
Asset Impairment Charge	$0	$232,000	$0	$4,698,000
Amortization Of Securities	$-773,000	$-123,000	$-1,703,000	-
Depreciation Amortization Depletion	$704,000	$660,000	$720,000	$1,031,000
Depreciation And Amortization	$704,000	$660,000	$720,000	$1,031,000
Gain Loss On Sale Of PPE	$37,000	$9,000	$102,000	$0
Net Income From Continuing Operations	$-55,480,000	$-15,628,000	$-62,106,000	$-117,793,000
Repayment Of Debt	-	-	$-290,000	$-222,000
Common Stock Payments	-	-	$0	$0
Net Issuance Payments Of Debt	-	-	$-290,000	$-222,000
Net Long Term Debt Issuance	-	-	$-290,000	$-222,000
Long Term Debt Payments	-	-	$-290,000	$-222,000
Net Intangibles Purchase And Sale	-	-	$0	$0
Purchase Of Intangibles	-	-	$0	$0
Change In Other Current Assets	-	-	$120,000	$2,698,000
Other Non Cash Items	-	-	$-2,007,000	$-1,331,000
Unrealized Gain Loss On Investment Securities	-	-	$0	$0
Amortization Cash Flow	-	-	$9,000	$9,000
Amortization Of Intangibles	-	-	$9,000	$9,000
Depreciation	-	-	$979,000	$1,022,000
Gain Loss On Investment Securities	-	-	$-1,000	$-22,000
Net Foreign Currency Exchange Gain Loss	-	-	$-367,000	$-1,469,000

Fetched: 2026-06-19